Research
Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
Scott Klarenbach, Chris Cameron, Sumeet Singh and Ehud Ur
CMAJ November 08, 2011 183 (16) E1213-E1220; DOI: https://doi.org/10.1503/cmaj.110178
Scott Klarenbach
MD MSc
Chris Cameron
BSc MSc
Sumeet Singh
BScPharm MSc
Submit a Response to This Article
Jump to comment:
No Responses have been published for this article.
In this issue
Article tools
Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin
Scott Klarenbach, Chris Cameron, Sumeet Singh, Ehud Ur
CMAJ Nov 2011, 183 (16) E1213-E1220; DOI: 10.1503/cmaj.110178
Jump to section
Related Articles
Cited By...
- Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
- Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!
- Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes
- Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis